Research Study

Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT02552849
Status 
Recruiting
Study Start/End 
Feb 11, 2016 to Jul 31, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Giselle Gerdak, Research Coordinator
Phone 
604-875-5091
Purpose of Study 

This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and reporting observed predicted forced vital capacity (FVC) change from baseline on an ongoing basis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.